Background Inhalation of N-acetylcysteine (NAC) has been carried out in our department since 1994 for treating interstitial pneumonia such as idiopathic pulmonary fibrosis (IPF). In this study, the clinical efficacy and safety of long-term NAC inhalation monotherapy for IPF was investigated. Methods NAC inhalation was carried out in 23 of 34 cases diagnosed as IPF by surgical lung biopsy in our department between 1994 and 2008. The treatment was continued for one year or longer in 14 cases. In these 14 cases and in 11 cases without treatment, the clinical courses, prognosis, lung function (%FVC, %DLco, and %TLC), and changes in serum markers for interstitial pneumonia (KL-6 and SP-D) were examined. Results There were no significant differences in survival curves between the two groups. Acute exacerbation was observed in 4 of 14 cases (28.6%) receiving NAC inhalation. Compared with the results just before the beginning of NAC inhalation, Δ%FVC and Δ%DLco in the treated cases were -4.7% and -2.9% one year later and -4.0% and -5.8% two years later, respectively. In cases without treatment, Δ%FVC and Δ%DLco were -3.5% and +5.3% one year later and +0.2% and +1.0% two years later, respectively. Conclusion Since this study is an open case-control study in a single institute and the number of cases is not large, its use in evaluating the efficacy of NAC inhalation monotherapy is limited. In addition, the role of NAC inhalation in combination with a steroid, an immunosuppressive agent, and a new anti-fibrosis drug should also be investigated.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial pneumonia with a poor prognosis (1) . The median survival of patients with IPF is 3-5 years after the onset of symptoms (2) . Since it is difficult to improve the survival time by anti-inflammatory therapy with a simple combination of a corticosteroid and an immunosuppressant such as cyclophosphamide and azathioprine (2) , treatment with N-acetylcysteine (NAC), pirfenidone, and endothelin receptor antagonists have received attention as a new strategy targeting alveolar-epithelium injury and control of abnormalities of fibroblasts (3) (4) (5) .
It has been proposed that a pathogenetic mechanism of IPF is repeated epithelial injury with oxidant-antioxidant imbalance (6) . NAC, is a precursor to the major antioxidant glutathione, which may be reduced in the lung of patients with IPF (7, 8) . A recent multicenter randomized trial, the IFIGENIA study, tested the effect of oral high-dose NAC versus placebo in patients receiving prednisone and azathioprine (3) . This study demonstrated significantly better preserved vital capacity (VC) and diffusing capacity for carbon monoxide (DLco). However, a substantial number of patients dropped out of the study, and the effect on the outcome of the patients who withdrew from the study is not known. Therefore, a combination corticosteroid, azathioprine and NAC therapy in patients with IPF is not recommended.
Inhaled NAC has been used for many years as a mucolytic agent in Japan that is largely free of adverse effects. Therefore, inhalation of NAC has been employed since 1994 in our department for interstitial pneumonia such as IPF. In the present study, we evaluated the clinical effect of longterm NAC inhalation monotherapy for 1 year or longer in patients with IPF diagnosed by surgical lung biopsy. We also evaluated problems with the continuation of NAC inhalation monotherapy.
Materials and Methods

Patients
We conducted a retrospective study of 34 patients diagnosed as IPF by surgical lung biopsy in our hospital between 1994 and 2008. Histologic evidence demonstrated the characteristics of usual interstitial pneumonia (UIP) and showed the various stages of interstitial lung disease including alveolitis, fibrosis, honeycombing, and a patchy reticular pattern that was predominantly evident in the basal region of the periphery of the lung fields. Patients who had received any corticosteroids or immunosuppressant drugs prior to lung biopsy were ineligible. Patients were excluded if they had clinical or serologic evidence of collagen vascular disease, a history of exposure to known fibrogenic agents, active infection, malignancy, hypersensitive pneumonitis or acute respiratory distress syndrome (ARDS). Pulmonary function tests (percentage of predicted forced vital capacity [%FVC] , percentage of predicted carbon monoxide diffusing capacity[%DLco], percentage of predicted total lung capacity [%TLC] ) and blood gas analysis (PaO2) were performed on enrollment into this study. Clinical features, changes in pulmonary function tests (ΔFVC, Δ%FVC, Δ%DLco, and Δ %TLC), changes in serum markers for interstitial pneumonia (KL-6 and SP-D), and prognoses of all patients were retrospectively evaluated. Acute exacerbation was defined using the following criteria proposed by IPF Clinical Research Network (9) [1] previous or concurrent diagnosis of IPF, [2] unexplained worsening or development of dyspnea with 30 days, [3] high-resolution computed tomography with new bilateral ground-glass abnormality and/or consolidation superimposed on a background reticular or honeycomb pattern consistent with UIP pattern, and [4] no evidence of alternative causes, including the following: left heart failure, pulmonary embolism, identifiable causes of acute lung injury.
Therapeutic regimen and evaluation
NAC inhalation monotherapy was carried out in 23 of 34 cases. The therapy was delivered via a compressor-type nebulizer (OMRON, Tokyo). Patients inhaled 352.4 mg NAC diluted with saline to a total volume of 10mL twice a day. This type of nebulizer produces aerosol particles of 1-10 μm and the 50% particle diameter is 5.21 μm. The treatment was continued for one year or longer in 14 of 23 cases. In these 14 cases and in 11 cases without treatment, the clinical features, changes in pulmonary function tests (% FVC, %DLco, and %TLC), changes in serum markers for interstitial pneumonia [KL-6 and surfactant protein-D (SP-D)], and prognoses of all patients were retrospectively evaluated. Efficacy was assessed by changes in results of pulmonary function tests from baseline to 12 months or 24 months. Serum KL-6 was measured by a sandwich electrochemiluminescence immunoassay (ECLIA) for routine laboratory use (Picolumi KL-6, Sanko, Tokyo, Japan). SP-D was measured by an enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies to human SP-D (SP-D EIA Kit, Yamasa, Tokyo, Japan). Although unavoidable administration of corticosteroids or immunosuppressive drugs for acute exacerbation or progression of the condition during the follow-up period was permitted, such treatment was prohibited in stable patients. Clinical data after the introduction of drug administration in cases with acute exacerbation, progress/deterioration, and administration of corticosteroids or immunosuppressants were excluded from analysis.
Safety was assessed by clinical symptoms (cough, dyspnea, appetite loss), drop out rate and fatal adverse events. Informed consent was obtained from all participants and the study protocol was approved by the local ethics committee. The withdrawal criteria for NAC inhalation were: withdrawal of the consent by the patient; judgment by the physician in charge to stop inhalation due to adverse events and safety reasons; and judgment of difficulty in inhalation due to acute exacerbation of IPF and aggravation from other causes.
Survival rates
The survival rate after treatment with or without NAC were compared by the log rank test and Kaplan-Meier survival curves were plotted. Survival status in August 2009 was established from clinical records.
Statistical methods
Data are presented as mean ± SD or as median (interquartile range). Differences between subjects in the two groups were examined by the Mann-Whitney U-test or the Chisquared test. Kaplan-Meier analysis was used to compare survival between the groups. Changes in parameters are expressed as an absolute value. ANOVA was used to compare the mean changes in values from baseline to 12 months or 24 months in the two treatment groups. Significance was defined as p<0.05.
Results
Status of NAC inhalation
There were 14 cases who were able to continue NAC inhalation one year or longer, and the average period of NAC inhalation was 29.9 months (12-88 months). Five cases continued the treatment for two years or longer. Death was the most frequent cause for stopping NAC inhalation, followed by adverse drug reactions such as sulfurous smell and cough. Of nine cases that continued NAC inhalation only for less than one year, continuing inhalation was difficult in four cases due to adverse effects such as cough and appetite loss.
T a b l e 1 . B a s e l i n e Ch a r a c t e r i s t i c s o f t h e S t u d y P o p u l a t i o n
KL-6 (U/m) SP-D (ng/mL) LDH (IU/L) FVC (L) %FVC (%) %DLco (%) %TLC (%) PaO2 (Torr)
Patients
Baseline characteristics of the study population are shown in Table 1 . There were no differences between these two groups.
Clinical course and prognosis
In terms of the subjective symptomatic changes in 14 cases that had been able to continue NAC inhalation for more than one year, dyspnea on exertion improved in 1 and deteriorated in 4 with no change in 9.
Clinical course is shown in Table 2 . Due to respiratory insufficiency, long-term oxygen therapy was introduced in four of 14 cases (28.6%) receiving NAC inhalation. During the follow-up, acute exacerbation was observed in four cases (28.6%). On the other hand, acute exacerbation was observed in two of 11 cases (18.2%) without treatment. Eleven cases receiving NAC inhalation and three without treatment died. There was no significant difference in the survival curves between the two groups, and the average survival period was 50.1 months after the beginning of NAC inhalation (Fig. 1) .
Changes in respiratory function test results
Year-to-year changes in respiratory test results (ΔFVC, Δ %FVC, Δ%DLco, and Δ%TLC) in the groups with and without NAC inhalation are shown in Table 3 . Δ%FVC and Δ%DLco were -4.7% and -2.9% one year later and -4.0% and -5.8% two years later, respectively, in the NAC inhalation group. In cases without treatment, Δ%FVC and Δ% DLco were -3.5% and +5.3% one year later and +0.2% and +1.0% two years later, respectively, and there were no significant differences between the two groups. Distribution of Δ%FVC from the beginning of observation is shown in Fig. 2 . In the NAC inhalation group, year-to-year changes were diverse and an improvement of 10% or more in %FVC one year later was observed in 1 of 6 cases. However, deterioration of 10% or more was found in one case receiving only NAC inhalation.
T a b l e 3 . Ye a r -t o -Ye a r Ch a n g e s i n Re s p i r a t o r y T e s t Re s u l t s i n t h e Gr o u p s wi t h a n d wi t h o u t NAC I n h a l a t i o n
Changes in serum markers for interstitial pneumonia
In one case receiving NAC inhalation, KL-6 improved remarkably after the treatment was started, but changes were inconsistent in other cases and there were no significant differences in year-to-year changes of KL-6 or SP-D between the two groups (Fig. 3) .
Comparison of Clinical Background between 4 Acute IPF Exacerbation and 10 Non-exacerbation Cases
There were no significant differences in clinical background between the cases who experienced exacerbations and those who did not. However, in three patients whose pulmonary function parameters were able to be sequentially measured, pulmonary function worsened before developing acute exacerbation (date not shown). 
F i g u r e 2 . Di s t r i b u t i o n o f Δ %F VC f r o m t h e b e g i n n i n g o f o b s e r v a t i o n . I n t h e NAC i n h a l a t i o n g r o u p , y e a r -t o -y e a r c h a n g e s we r e d i v e r s e a n d a n i mp r o v e me n t o f 1 0 % o r mo r e i n %F VC o n e y e a r l a t e r wa s o b s e r v e d i n 1 o f 6 c a s e s .
NAC(+) NAC(-) NAC(+) NAC(-)
F i g u r e 3 . Ch a n g e s i n s e r u m ma r k e r KL -6 . I n o n e c a s e r e c e i v i n g NAC i n h a l a t i o n , KL -6 i mp r o v e d r e ma r k a b l y a f t e r t h e t r e a t me n t s t a r t e d , b u t c h a n g e s we r e i n c o n s i s t e n t i n o t h e r c a s e s a n d t h e r e we r e n o s i g n i f i c a n t d i f f e r e n c e s i n y e a r -t o -y e a r c h a n g e s b e t we e n t h e t wo g r o u p s .
Comparison of Clinical Background between Cases who Continued NAC Treatment and those who did not
Cases that stopped NAC inhalation due to adverse events were compared with those that continued NAC inhalation for more than one year. Due to adverse events, NAC inhalation was stopped in 6 cases in total: 2 in 14 cases that continued NAC for more than one year and 4 in 9 cases that continued NAC inhalation for less than 1 year.
Five of 6 cases who discontinued NAC treatment were females and the 3 patients who developed coughing were female (Table 4 ). There were no significant differences in clinical background between the two groups except for FVC.
Discussion
In this study, the long-term clinical effects of NAC inhalation monotherapy for IPF were examined in IPF cases who were able to continue the therapy for one year or longer in our department. There were no significant differences in a survival curves between the 14 patients in the NAC inhalation group and the 11 patients in the non-treated group. In addition, significant improvement was not demonstrated by long-term changes in pulmonary function parame- T a b l e 4 . Cl i n i c a l B a c k g r o u n d b e t 
we e n Ca s e s wh o Co n t i n u e d NAC T r e a t me n t a n d T h o s e wh o Di d No t
NAC-continued (n=12)
NAC-discontinued (n=6)
Age ( ters in the NAC inhalation group compared with the nontreated group. NAC is a precursor of glutathione that attenuates tissue injury due to oxidative stress and exerts an antiinflammatory effect by inhibiting the expression of inflammatory cytokines and adhesion molecules via inhibition of transcription factor NF-κB-mediated signal transduction. To date, the clinical efficacy of NAC inhalation has only been reported from Japan. Tomioka et al reported a pilot study of aerosolized NAC for IPF of over 12 months (10) . This study demonstrated that neither changes in VC and DLco nor quality of life (QOL) in the NAC group were significantly different compared with controls receiving bromhexine hydrochloride. However, it was reported that NAC inhalation suppressed the reduction in SpO2 after six minutes of walking and improved serum KL-6 levels. Furthermore, in our cases KL-6 levels decreased in 4 cases that included 1 case with a marked decrease. In one case with a marked decrease in KL-6, HRCT showed that ground glass-like appearance was ameliorated. A decrease of circulating KL-6 in IPF is thought to be due to a decrease of KL-6 production by regenerating alveolar type II pneumocyte, and/or to reduced permeability following the destruction of the air-blood barrier in the affected lung (11) . Therefore, the treatment has the potential to protect repeated epithelial injury with oxidant-antioxidant imbalance and to delay the progression of IPF. There were no significant differences in the deterioration of Δ%FVC and Δ%DLco over time between the cases with and without NAC inhalation in the present study. However, this is an open trial and there are limits to the interpretation of the results. First, all of the IPF cases were diagnosed by video-assisted thoracoscopic surgery (VATS) and relatively mild cases accounted for a majority of the cases in this study. According to previous randomized control studies using IFN-γ, pirfenidone, NAC, etanercept and bosentan (3-5, 12, 13) , the yearly ΔFVC was presumed to be 160-200 mL in the placebo group. However, since FVC before the beginning of observation varied among cases, Δ%FVC was also variable, ranging from -4.98% to -7.7%. A phase III trial (CAPACITY) carried out in the U.S. revealed that differences in Δ%FVC in the placebo group resulted in different results in %FVC reduction by pirfenidone between CAPACITY 1 and CAPACITY 2 (14) . Taken together, it is clear that it is important to fully evaluate the appropriateness of a reduction in %FVC in the placebo group in evaluating drug efficacy by a reduction in %FVC. When the results in this study and those in the IFIGENIA study (3) using oral NAC and corticosteroid were compared, the average yearly reduction in %FVC in the placebo group was -190 mL in the IFIGENIA study, while it was -133 mL and -166 mL in the NAC treatment group and no treatment group, respectively, in the present study, suggesting that NAC inhalation therapy potentially suppresses the decline in FVC over time. NAC inhalation monotherapy may be an effective treatment for mild IPF. However, NAC monotherapy is weakly recommended due to the low quality of the evidence. Therefore, further clinical studies on NAC inhalaton therapy are warranted.
Problems with NAC inhalation include adverse effects, inhalation adherence, and methods and doses of inhalation. In the present study, a number of cases had difficulty in inhaling due to adverse effects at less than one year of inhalation, which should be seriously taken into account. Five of 6 of these patients were females and the 3 patients who developed coughing were female. In terms of inhalation doses, oral NAC at 1,800 mg/day was required to sufficiently ele-vate glutathione concentrations in the alveolar fluid (15) . A small amount of inhalation is expected to exert a beneficial effect, but larger amounts of the drug may reach alveoli under excellent ventilation conditions. Therefore, the optimal dose needs to be defined in future studies.
In this study, the clinical course and changes in the respiratory test results showed various patterns. Martinez et al (16) reported that there were mild reductions in %FVC and %DLco of -3.5% and -0.8%, respectively, in 168 mild to moderate IPF cases followed up for 72 months, but 21% died during the follow-up period and most died from IPFrelated causes including acute exacerbation of IPF. Therefore, it is very important to clarify treatment indication in evaluating the efficacy of drug therapy for IPF. As shown in this study, IPF is a disease with markedly heterogeneous manifestations. Mild IPF cases may include cases soon after the onset (early stage cases) and stable cases without progression over years (progression-free cases). In early stage cases, pulmonary function may deteriorate and it is worth investigating the necessity of early intervention such as NAC inhalation. However, in progression-free cases, early intervention may be unnecessary. Taken together, in investigating the efficacy of treatment for mild IPF cases, it is important to take into account the clinical information from six months and one year before treatment, instead of only evaluating clinical information at one time point just before the beginning of treatment, and to evaluate changes over a longer time period in each case. On the other hand, periodical lung function tests were not done after the introduction of NAC inhalation in some cases in this study. As for the potential reasons, some overlapping cases were included in the subjects and there were four cases undergoing long-term oxygen therapy due to advancement of the disease during the follow-up. It is difficult to carry out lung function tests periodically in these cases. In the future clinical study on severe or advanced IPF cases, it is expected that drop-out cases will appear at a certain frequency when lung function tests are adopted for evaluation criteria, which will potentially influence the interpretation of the results.
In this study, among the 14 patients who continued NAC inhalation monotherapy for 1 year or longer, 4 patients (28.6%) developed acute exacerbation of IPF. Since it has been reported that the natural course or progress of IPF varies from one patient to another, the concept of acute exacerbation of IPF is being accepted in the US and Europe (9, 17) The previously reported incidence of acute exacerbation of IPF varied between 5 and 61% depending on the study design and the number of study subjects (17) . Risk factors and methods for prevention of developing acute exacerbation are still largely unknown. We also failed to show any significant differences in clinical background or laboratory values before the inhalation treatment between the groups of patients with and without the acute exacerbation of IPF in the present study. In three patients whose pulmonary function parameters were able to be sequentially measured, however, function worsened before developing acute exacerbation. Therefore, attention should be paid to the possible development of acute exacerbation in patients whose pulmonary function worsens even during NAC inhalation therapy.
Lastly, since this study is an open case-control study in a single institute and the number of cases is not large, its use in evaluating the clinical efficacy of NAC inhalation monotherapy is limited. In addition, the role of NAC inhalation in combination with a corticosteroid, an immunosuppressive agent, and a new anti-fibrosis drug should also be investigated, because some mild cases were stable even without treatment, while other cases worsened soon despite NAC inhalation monotherapy.
